TCG Labs Soleil Secures $400M in Funding, Expands Global R&D Footprint

TCG Labs Soleil, a San Francisco-based biotech venture firm, has successfully raised $400 million in its latest funding round, matching the size of its inaugural fund from the previous year. This significant capital injection aims to bolster the company's ability to advance its portfolio of biotech companies and expand its research and development capabilities on a global scale.

Strategic Focus on Single-Asset Biotechs

TCG Labs Soleil operates on a venture-biotech model, collaborating closely with The Column Group, a prominent venture capital firm in the industry. The company's primary focus is on supporting single-asset biotechs through the critical phase of clinical proof of concept, typically occurring in phase 2 trials. This strategic approach positions TCG Labs Soleil's portfolio companies as attractive candidates for potential partnerships within the pharmaceutical industry.

Since its inception in 2023, TCG Labs Soleil has demonstrated remarkable growth, establishing more than 10 portfolio companies across various therapeutic indications and modalities. This rapid expansion underscores the firm's commitment to fostering innovation in the biotech sector.

Global Expansion and R&D Enhancement

In a move to strengthen its international presence, TCG Labs Soleil has established a new research and development site in Shanghai, China. This expansion is part of the company's broader strategy to create a global network that supports both internally developed programs and externally sourced opportunities.

The decision to set up operations in China reflects the growing importance of the Asian market in the global pharmaceutical landscape and positions TCG Labs Soleil to tap into the region's rich talent pool and research capabilities.

Recent Strategic Partnerships

TCG Labs Soleil's portfolio companies have already begun to make waves in the industry through strategic collaborations. In May 2025, Juri Biosciences, one of TCG Labs Soleil's portfolio companies, entered into a licensing agreement with EpimAb Biotherapeutics, a Chinese biotech firm. The deal, potentially worth up to $210 million, grants Juri Biosciences exclusive rights to EpimAb's T-cell engager designed for the treatment of metastatic prostate cancer.

This partnership exemplifies TCG Labs Soleil's commitment to fostering collaboration between its portfolio companies and established biotech firms, particularly in the Asian market.

Peter Svennilson, managing partner at TCG Labs, emphasized the flexibility of their business model, stating, "The TCG Labs Soleil model gives us the flexibility and control to invest decisively in the highest-potential single-asset programs, while remaining agile in how and when we engage with biopharma partners." He added, "With this new funding, we can continue building the portfolio and position each program for success, whether through in-house development or an early strategic transaction."